A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study
Phase of Trial: Phase III
Latest Information Update: 19 May 2017
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Expanded access
- Sponsors GlaxoSmithKline
- 19 May 2017 This trial was completed in Estonia, according to European Clinical Trials Database.
- 10 Apr 2017 Status changed from active, no longer recruiting to recruiting.
- 20 Feb 2017 Status changed from recruiting to active, no longer recruiting.